Scientists screened a collection of pharmacologically active compounds to identify those that regulate invadopodia formation, a driving force behind cancer metastasis. First, the team identified several new invadopodia inhibitors that target a family of enzymes called cyclin-dependent kinases. Secondly, one of the pro-invadopodia compounds identified in the screen was the chemotherapeutic agent paclitaxel — a finding that might impact the drug’s use in treating cancer.